Evolocumab Reduces Risk of First Major Cardiovascular Events by 31% in Patients Without Significant Atherosclerosis
Results from VESALIUS-CV
In a subgroup analysis of VESALIUS-CV, 3,655 patients with diabetes but no known significant atherosclerosis were followed for a median of 4.8 years. Evolocumab reduced 3-P MACE by 31% (HR 0.69; P=0.009) and 4-P MACE by 31% (HR 0.69; P=0.001). The effect appeared after 1 year and grew to ~40% reduction thereafter. CV death was reduced by 32% and all-cause mortality by 24%. This supports the use of PCSK9 inhibitors for primary prevention in high-risk diabetes patients.
Background
Intensive LDL-C lowering with PCSK9 inhibitors has largely been reserved for patients with significant atherosclerosis. We investigated whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without significant atherosclerosis.
Methods
VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab in 12,257 patients with qualifying atherosclerosis or diabetes, no prior MI or stroke, and LDL-C >=90 mg/dL. In this subgroup analysis, we examined outcomes in patients without known significant atherosclerosis (eg, any arterial stenosis >=50% or CAC >=100). The dual primary endpoints were composites of coronary heart disease death, MI, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE).
Results
This cohort included 3,655 patients (median age 65 yrs, 57% female) followed for a median of 4.8 yrs. Among those in the lipid substudy, LDL-C at 48 wks was 52 vs. 111 mg/dL in the evolocumab vs. placebo arms (p<0.0001). Evolocumab significantly reduced the risk of 3-P MACE and 4-P MACE each by 31% (HR 0.69 [0.52-0.91], p=0.009; HR 0.69 [0.55-0.86], p=0.001). The effect became apparent after 1 year, with 41% and 39% reductions in the risk of 3-P MACE and 4-P MACE thereafter. The HR for CV death was 0.68 (0.46-0.99) and the HR for all-cause mortality was 0.76 (0.61-0.95).
Conclusions
In patients without significant atherosclerosis, evolocumab substantially reduced the risk of a first major CV event.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
